Oppenheimer initiated coverage on Relay Therapeutics with a new price target
$RLAY
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Oppenheimer initiated coverage of Relay Therapeutics with a rating of Outperform and set a new price target of $33.00